Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

ABMC Reports Fourth Quarter and Year End 2019 Results
BiotechnologyEarnings

ABMC Reports Fourth Quarter and Year End 2019 Results

June 26, 2020 5:00 PM

KINDERHOOK, NY / ACCESSWIRE / June 26, 2019 / American Bio Medica Corporation (OTC PINK:ABMC) today announced financial results for the fourth quarter and year ended December 31, 2019. Chief Executive Officer, Melissa A. Waterhouse stated, "While sales did not increase in Q4 2019 (as they did in Q3 2019), they were relatively flat. In 2019, sales in our core markets declined, some of which was due to timing of shipments to customers at the...

Read more
Quanta Inc Launches New molequle Brand for Amazon
BiotechnologyProduct Announcements

Quanta Inc Launches New molequle Brand for Amazon

June 25, 2020 8:30 AM

BURBANK, CA / ACCESSWIRE / June 25, 2020 / Quanta Inc. (OTC PINK:QNTA), an applied sciences company based on a quantum biology platform that significantly boosts the potency and efficiency of any plant-based matter, announced the launch of molequle, a new skincare brand initially featuring masks and under eye patches. The products, made with all-natural ingredients and featuring Quanta's polarization technology, are slated to debut on Amazon's...

Read more
Tetra Bio-Pharma Announces Stock Option Grant
BiotechnologyCompany Update

Tetra Bio-Pharma Announces Stock Option Grant

June 25, 2020 8:00 AM

OTTAWA / ACCESSWIRE / June 25, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP) (OTCQB:TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, is pleased to announce the grant of an aggregate of 1,535,583 stock options (each, an "Option") to certain Officers, consultants and employees of the Company in accordance with the Company's shareholder approved stock option plan. Each Option is exercisable...

Read more
Wuhan General Group Signs Manufacturing, Distribution and Sales Agreement with Cafféluxe
BiotechnologyCompany Update

Wuhan General Group Signs Manufacturing, Distribution and Sales Agreement with Cafféluxe

June 24, 2020 8:30 AM

MONTREAL, QC / ACCESSWIRE / June 24, 2020, / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce, that effective June 22nd, 2020, it has entered into a manufacturing, distribution and sales agreement with Cafféluxe for an initial two-year term. Under the terms of this agreement, Cafféluxe will...

Read more
Tetra Bio-Pharma Announces Change to its Board of Directors
BiotechnologyManagement Changes

Tetra Bio-Pharma Announces Change to its Board of Directors

June 22, 2020 8:00 AM

Change represents evolving board capabilities as Tetra enters next stage of its corporate development OTTAWA, ON / ACCESSWIRE / June 22, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, today announces the departure of one of its members of the Board of Directors (the "Board). The Tetra Board has received...

Read more
Wuhan General Group Announces Name Change and Rebranding to M2Bio Sciences
BiotechnologyCompany Name Change

Wuhan General Group Announces Name Change and Rebranding to M2Bio Sciences

June 18, 2020 8:30 AM

MONTREAL, QC / ACCESSWIRE / June 18, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce a corporate name change and rebranding of the company to M2Bio Sciences, Inc ("M2Bio"). The name change was effective June 17, 2020, with the State of Nevada. In addition to the new corporate name, the...

Read more
Tetra Bio-Pharma's Management Provides Regulatory Update of ARDS-003 for the Potential Prevention and Treatment of Cytokine Release Syndrome
BiotechnologyCompany Update

Tetra Bio-Pharma's Management Provides Regulatory Update of ARDS-003 for the Potential Prevention and Treatment of Cytokine Release Syndrome

June 17, 2020 8:00 AM

OTTAWA, ON / ACCESSWIRE / June 17, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, today provides an update on the development of its ARDS-003 intravenous drug product for the potential treatment of cytokine release syndrome (CRS) and the potential prevention of Acute Respiratory Distress Syndrome (ARDS) development in...

Read more
Xenetic Biosciences, Inc. Announces Collaboration with Pharmsynthez and Multiple Academic Institutions in Russia and Belarus to Advance Development of XCART(TM) Platform
BiotechnologyPartnerships

Xenetic Biosciences, Inc. Announces Collaboration with Pharmsynthez and Multiple Academic Institutions in Russia and Belarus to Advance Development of XCART(TM) Platform

June 16, 2020 8:05 AM

Goal of XCART collaboration to optimize XCART process, develop manufacturing processes and to ultimately dose non-Hodgkin lymphoma (NHL) patients Pharmsynthez to act as primary contract research organization coordinating activities throughout collaboration Academic Institutions include: Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences (IBCh RAS) Belarussian Research Center for...

Read more
ENB Therapeutics Announces Successful Completion of the First Dosing Cohort in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab
BiotechnologyCompany Update

ENB Therapeutics Announces Successful Completion of the First Dosing Cohort in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab

June 15, 2020 3:45 PM

ENB-003 is the Company's first in class small molecule therapeutic selectively targeting the ETB receptor - a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / June 15, 2020 / ENB Therapeutics, INC., a biotechnology company pioneering a new and differentiated class of therapeutics targeting the ETB receptor (ETBR), today announced the successful completion of the first dosing cohort in a Phase I dose escalation of ENB-003 in combination...

Read more
Edesa Biotech Receives Regulatory Approval to Initiate COVID-19 Study
BiotechnologyCompany Update

Edesa Biotech Receives Regulatory Approval to Initiate COVID-19 Study

June 15, 2020 8:15 AM

TORONTO, ON / ACCESSWIRE / June 15, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received expedited approval from Health Canada to begin a Phase 2/3 clinical study of its investigational drug, EB05, which the company is developing as a potential treatment for moderate to severe COVID-19 patients. The company reported that it has EB05 drug product available now and is seeking government grants to...

Read more
Preferred Commerce Releases the Most Advanced Superoxide Dismutase (SOD) Product Line Worldwide With the Launch of Its THRIV5 Supplements
BiotechnologyProduct Announcements

Preferred Commerce Releases the Most Advanced Superoxide Dismutase (SOD) Product Line Worldwide With the Launch of Its THRIV5 Supplements

June 11, 2020 10:40 AM

Preferred Commerce Releases the Most Advanced Superoxide Dismutase (SOD) Product Line Worldwide With the Launch of Its THRIV5 Supplement Line Breakthrough formulation of SOD and additional key ingredients could boost the immune system beyond anything ever recorded. The THRIV5 product line could very well be the most powerful all-natural supplement to repair and help restore well-being in the human body. WELLINGTON, FL / ACCESSWIRE / June...

Read more
Mymetics Receives Support for Virosome-based Covid-19 Vaccine Development from European Vaccine Infrastructure Project (Transvac2)
BiotechnologyCompany UpdateProduct Announcements

Mymetics Receives Support for Virosome-based Covid-19 Vaccine Development from European Vaccine Infrastructure Project (Transvac2)

June 11, 2020 2:00 AM

Mymetics Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine The European vaccine infrastructure, TRANSVAC2, funded by the European Commission through the Horizon 2020 framework, will provide Mymetics access to high quality technical vaccine development services in the fields of...

Read more
Dyadic and Frederick National Laboratory to Develop Cell Lines for COVID-19 Vaccine Candidates Using Dyadic's C1 Gene Expression Platform
BiotechnologyCompany Update

Dyadic and Frederick National Laboratory to Develop Cell Lines for COVID-19 Vaccine Candidates Using Dyadic's C1 Gene Expression Platform

June 10, 2020 8:30 AM

JUPITER, FL / ACCESSWIRE / June 10, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that it was selected by the...

Read more
Wuhan General Group Signs Distribution Agreement with Medigrow for International Distribution Rights of Medical Cannabis Products
BiotechnologyCompany Update

Wuhan General Group Signs Distribution Agreement with Medigrow for International Distribution Rights of Medical Cannabis Products

June 10, 2020 8:30 AM

MONTREAL, QC / ACCESSWIRE / June 10, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research, is pleased to announce the signing of a distribution agreement with Medigrow Africa ("Medigrow"), an African based medical cannabis company with a formal network of legal African cannabis growers producing international...

Read more
Calmare Therapeutics Awarded $2.5 Million, Five-Year Contract by U.S. Department of Veteran Affairs for Calmare(R) Pain Therapy Devices
BiotechnologyCompany Update

Calmare Therapeutics Awarded $2.5 Million, Five-Year Contract by U.S. Department of Veteran Affairs for Calmare(R) Pain Therapy Devices

June 9, 2020 1:05 PM

Contract No.: 36F797-20D0118 | Contract Term: Five Years FAIRFIELD, CT / ACCESSWIRE / June 9, 2020 / Calmare Therapeutics Incorporated, (OTC:CTTC), the pain mitigation company, was awarded a five-year, $2.5 million Federal Supply Schedule contract by the U.S. Department of Veteran Affairs for Calmare® Pain Therapy Devices. The contract was awarded under Schedule 65 II A - Medical Equipment and Supplies under Federal Supply Schedule...

Read more
Midatech Pharma PLC Announces Purported Termination of MTX110 Licence Agreement
BiotechnologyRegulatory

Midatech Pharma PLC Announces Purported Termination of MTX110 Licence Agreement

June 9, 2020 11:35 AM

This Announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Upon the publication of this Announcement, this inside information is now considered to be in the public domain. ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 9, 2020 / Midatech Pharma PLC (AIM:MTPH.L) (NASDAQ:MTP) (the "Company"), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines...

Read more
ZIVO Bioscience Receives Notice of Allowance for Cytokine Modulation Patent Application From US Patent Office, Commences Bioproduct Scaleup
BiotechnologyCompany Update

ZIVO Bioscience Receives Notice of Allowance for Cytokine Modulation Patent Application From US Patent Office, Commences Bioproduct Scaleup

June 9, 2020 8:30 AM

KEEGO HARBOR, MI / ACCESSWIRE / June 9, 2020 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of therapeutic and nutritional products derived from its proprietary algal cultures, announces today that the U.S. Patent and Trademark Office issued a Notice of Allowance for U.S. Patent application "Compounds and Methods for Affecting Cytokines" (Application Serial No. 16/273,794). A...

Read more
Versatope Therapeutics Rapidly Addressing Pandemic Threats at BIO Digital 2020
BiotechnologyCompany UpdateConferences

Versatope Therapeutics Rapidly Addressing Pandemic Threats at BIO Digital 2020

June 8, 2020 4:30 PM

NOTE: CEO Christopher Locher to Present at BIO Digital this week. LOWELL, MA / ACCESSWIRE / June 8, 2020 / Versatope Therapeutics, Inc, a biotechnology company developing vaccines and therapeutics, announced Christopher Locher, Ph.D., CEO of Versatope Therapeutics, Inc., will present at the 2020 BIO Digital Conference being held June 8-12, 2020. Click here to view the full multimedia, interactive announcement. Key...

Read more
Pieris Pharmaceuticals Announces Virtual 2020 Annual Meeting of Stockholders
BiotechnologyShareholder Meeting

Pieris Pharmaceuticals Announces Virtual 2020 Annual Meeting of Stockholders

June 8, 2020 4:30 PM

BOSTON, MA / ACCESSWIRE / June 8, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer, and other diseases, announced today that due to the public health impact of the COVID-19 pandemic and to support the health and well-being of its stockholders, the 2020 Annual Meeting, scheduled for June 23, 2020...

Read more
Xenetic Biosciences, Inc. to Present at the Virtual Investor Fireside Chat Series
BiotechnologyCompany Update

Xenetic Biosciences, Inc. to Present at the Virtual Investor Fireside Chat Series

June 8, 2020 8:35 AM

Live video moderated discussion with CEO, Jeffrey Eisenberg, on Tuesday, June 16th at 12:00 PM ET, immediately followed by an interactive Q&A session FRAMINGHAM, MA / ACCESSWIRE / June 8, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced that...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?